Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-11-06
2002-12-17
Barts, Samuel (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S004100, C536S118000, C536S122000, C536S017200, C514S062000, C514S885000, C514S547000, C514S025000
Reexamination Certificate
active
06495678
ABSTRACT:
FIELD OF INVENTION
This invention relates to an immunosuppressant comprising Glucopyranose derivatives of the formula (I):
wherein all symbols are as hereinafter defined, or non-toxic salts thereof as active ingredient.
BACKGROUND
An immunoreaction is a system to protect the organism from a foreign matter as a protective reaction. However, sometimes an injury is happened for an organism by an immunoreaction that naturally plays to protect an organism. As diseases caused by the above injury, there are allergic diseases and autoimmune disease.
Recently, allergic diseases, e.g. allergic asthma, atopic dermatitis containing urticaria, allergic rhinitis, allergic conjunctivitis, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, are increased. It is consider that these diseases are caused by peculiarity IgE antibody against an antigen in blood. Then there is lot of case that interleukin 5 (IL-5) and eosinophils are increased in a chronic condition. And the increase is also showed in a mild case. Allergic bronchopulmonary aspergillosis is asthma as a spore of aspergillosis is an antigen, and it possesses a peculiarity IgE antibody. And it showed an acute cutireaction. The treatment is same method with generally bronchial asthma [Saishin Naikagaku Taikei 61 (Nakayama): pneumonia·interstitial pneumonia, 157-158 (1992); Saishin Naikagaku Taikei 62 (Nakayama): bronchial asthma·allergic asthma, 81-91 (1992)].
One of the allergic diseases excepted the above, with the proviso that a part is overlapped, is hyper IgE syndrome containing purulence, low of wandering of leukocyte and atopic dermatitis. It is showed an abnormal mechanism of neutrophil. It is characteristic to show hyper IgE in blood, an atopic dermatitis like eczema and an infection by recurrent yellow staphylococcosis [Tadamichi MASU et al., hyper IgE syndrome, new allergic dermatitis (editor is Hikotaro Yoshida), 143 (1991)].
Besides, PIE syndrome, pulmonary eosinophilia, e.g. Loeffler syndrome, chronic eosinophilic pneumonia, acute eosinophilic pneumonia, tropical eosinophilia, allergic granulomatous angiitis, allergic bronchopulmonary mycosis, eosinophilia; and eosinophilic fasciitis accompanying increases of IL-5 and IgE antibody in a serum are known as allergic diseases [Enright T. et al., “Pulmonary eosinophilic syndrome” Ann. Allergy, 62, 277 (1989), and Saishin naikagaku taikei 24 (Nakayama): collagen diseases, similarity diseases thereof, 112-116 (1992)].
Allergic diseases that caused by abnormal enhancement of immunity, such as an increase of IgE antibody that is peculiarity against an antigen, increases of IL-5 and eosinophils, are increased.
General treatments of allergic diseases are carried out to prevent an inhalation or take of antigen, e.g. cedar pollens, acarid, spore of aspergillosis and some foods; into body, and to use medicines, e.g. anti-histamine, steroid.
However, a fundamentally treatment is difficult. As mentioned above, if abnormal enhancement of immunity, e.g. increases of IgE antibody that is peculiarity against an antigen, IL-5 and eosinophils, are main reasons of allergic diseases, use of medicines possessed an inhibitory activity of enhancement of immunity has a possibility to be a fundamentally treatment of allergic diseases.
On the other hand, T cells also play an important roll on an immunoreaction. An activated T cells product various cytokines, such as interleukin 4 (IL-4), interleukin 2 (IL-2), interferon &ggr; (IFN-&ggr;), and assist an activity of immunoreaction.
The other way, a production of these cytokines also causes allergic diseases and autoimmune disease. IL-4 is related mainly to an activity of B cells stimulated by antigen, and it promotes a production of IgE. IL-2 has an increasing activity for T cells and B cells stimulated by antigen. IFN-&ggr; causes an inducement of differentiates of killer T cells and an activity of macrophage.
Accordingly, it is expected to improve allergic diseases, such as diseases described hereinbefore and autoimmune disease, e.g. chronic rheumatism, psoriasis, multiple sclerosis, and ulcerative colitis, which related to immunoreaction.
Glucopyranose derivatives of the present invention of the formula (I)
wherein all symbols are as hereinafter defined; or non-toxic salts thereof are disclosed to have an activity of lipid A like, and an activation of immune, e.g. activation of macrophage, a blastogenesis action of B cells, an product action of non-peculiar antibody, an activation of cell-mediated immunity; antineoplastic activity, e.g. an activation of inducement of interferon, an activation of product of interleukin, an activation of inducement of TNF; in Japanese Kokoku-koho Hei 4-74359 (EP 0226381) or Japanese Kokai-koho Hei 1-52793 (EP 0288888).
Besides, in the compound of the formula (I), various non-toxic salts of 2-deoxy-2-[3S-(9-phenylnonanoyloxy)tetradecanoyl]amino-3-O-(9-phenylnonanoyl)-4-O-sulfo-D-glucopyranose of the formula (I-A)
are disclosed in Japanese Kokai-koho Hei 6-41175 (EP 0226381).
However, there is no report that Glucopyranose derivatives of the present invention of the formula (I) or non-toxic salts thereof possess an activity of immunosuppression.
DISCLOSURE OF THE INVENTION
Energetic investigations have been carried out in order to make a compound having an activity of immunosuppression, e.g. IgE antibody production inhibition, and a high safety. The present inventors have found that Glucopyranose derivatives of the formula (I) or non-toxic salts thereof accomplished the present purpose.
The present invention relates to an immunosuppressant comprising Glucopyranose derivatives of the formula (I):
wherein R is hydrogen, hydroxy or C1-4 alkoxy,
G is (1)
in which R
1
is a single bond or C2-20 oxycarbonylalkyl,
R
2
is hydrogen or
in which R
8
is hydrogen, C1-7 alkyl, C1-7 alkoxy or halogen atoms, m is 1, 2 or 3;
R
3
is C1-20 alkylene,
R
4
is hydrogen or
in which R
9
is hydrogen, C1-7 alkyl, C1-7 alkoxy or halogen atoms, n is 1, 2 or 3; or
(2)
in which Y is a single bond or C1-4 alkylene, p and q independently, is an integral of 6-12;
R
5
is C2-20 oxycarbonylalkyl,
R
6
is hydrogen or
in which R
8
and m are as hereinbefore defined; or
R
5
-R
6
is
in which Z is a single bond or C1-4 alkylene, r and s, independently, is an integral of 6-12;
R
7
is hydrogen, methyl, hydroxymethyl or sulfoxymethyl;
with the proviso that (1) R
2
, R
4
and R
6
is not hydrogen at the same time,
(2) when R
1
is C2-20 oxycarbonylalkyl, then R
2
bonds to alkyl in R
1
,
(3) when R
5
is C2-20 oxycarbonylalkyl, then R
6
bonds to alkyl in R
5
;
or non-toxic salts thereof as active ingredient.
REFERENCES:
patent: 4925929 (1990-05-01), Toda et al.
patent: 5158941 (1992-10-01), Jadhav et al.
patent: 5294723 (1994-03-01), Imaki et al.
patent: 0 444 208 (1991-09-01), None
patent: 0 553 786 (1993-08-01), None
patent: 63-179885 (1988-07-01), None
patent: 64-52793 (1989-02-01), None
patent: WO 97/18222 (1997-05-01), None
patent: 99/18975 (1999-04-01), None
Patent Abstracts of Japan—11106394 (Apr. 20, 1999).
Patent Abstracts of Japan—09157284 (Jun. 17, 1997).
European Search Report dated Dec. 13, 2001.
Omawari Nagashige
Soma Gen-ichiro
Barts Samuel
Khare Devesh
Ono Pharmaceutical Co. Ltd.
LandOfFree
Immunosuppressant containing glucopyranose derivative as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunosuppressant containing glucopyranose derivative as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunosuppressant containing glucopyranose derivative as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2952923